EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features

Prasiksha Sitaula iD, Manisha Gadgeel iD, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Kathryn White, Yubin Ge iD, Jeffrey W Taub iD, Katherine Gurdziel iD, Hunter Dlugas iD, Greg Dyson iD und 4 weitere

Cancers · 28.04.2026 · 18 (9) · 1396

DOI: 10.3390/cancers18091396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 28.04.2026. Verfasst von Prasiksha Sitaula und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI 48201, USA. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Foundation, Children’s Foundation, Development of AML Cell lines with Acquired Resistance to Standard Therapies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute erythroid leukemia (AEL) or AML-M6 predominantly affects older adults and is rare in childhood. Compared with other AML subtypes, AEL remains relatively understudied because of its rarity. We established LS-CHM, a novel AEL cell line derived from the ascitic fluid of a patient with congenital leukemia. Interestingly, leukemic cells persisted in the ascitic fluid even after successful eradication from the bone marrow and extramedullary sites.

Method

Leukemia cells from the ascites fluid exhibited robust proliferation in culture independent of cytokine requirement and were further characterized by flow cytometric immunophenotyping, cytogenetics, cell cycle and doubling time analysis, colony formation, genome and RNA sequencing, myeloid gene next generation sequencing, and cytotoxicity analysis.

Results

LS-CHM displayed CD36, partial CD235a, CD31, CD43, and CD71 expression and demonstrated in vitro robust growth and high sensitivity to chemotherapeutic agents. A PDX mouse model showed development of leukemia. Genomic analysis revealed a frameshift BCOR mutation in the absence of additional mutations and downregulated TP53 expression with an exonic non-deleterious mutation. RNA sequencing of LS-CHM cells revealed upregulation of two cohesin complex genes, RAD21 and SMC3, whose high levels are associated with hematopoietic stem cell differentiation into erythroid lineage.

Conclusions

LS-CHM represents the first congenital AEL-derived cell line, in contrast to the predominantly adult-origin and often secondary erythroid leukemia cell lines available currently. Thus, LS-CHM provides a unique pediatric and extramedullary AEL model, expanding the existing spectrum of AEL cell lines and offering valuable opportunities for biologic and therapeutic investigations.

Schlagwörter

Stichwörter der Autor:innen

acute erythroid leukemiaascitic fluidcell linecongenital leukemiaextramedullary disease

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI 48201, USA.
  • Division of Hematology/Oncology, Flow Cytometry Laboratory, Children's Hospital of Michigan, Detroit, MI 48201, USA.
  • Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
  • Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
  • School of Medicine, Wayne State University, Detroit, MI 48201, USA.
  • Genome Sciences Core, Department of Pharmacology and IEHS, Wayne State University, Detroit, MI 48201, USA.

ORCID-Profile: Prasiksha Sitaula, Manisha Gadgeel, Yubin Ge, Jeffrey W Taub, Katherine Gurdziel, Hunter Dlugas, Greg Dyson, David Carr, Süreyya Savaşan

Förderung

  • Children's Foundation
  • Children’s Foundation, Development of AML Cell lines with Acquired Resistance to Standard Therapies

Zitieren

APA

Sitaula, P., Gadgeel, M., Edwards, H., Polin, L., Kushner, J., Dzinic, S. H., White, K., Ge, Y., Taub, J. W., Gurdziel, K., Dlugas, H., Dyson, G., Arlene, R., Carr, D., Moussa, O., & Savaşan, S. (2026). Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features. Cancers, 18(9), 1396. https://doi.org/10.3390/cancers18091396

Vancouver

Sitaula P, Gadgeel M, Edwards H, Polin L, Kushner J, Dzinic SH, et al. Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features. Cancers. 2026;18(9):1396. doi:10.3390/cancers18091396

BibTeX
@article{Sitaula2026,
  author = {Sitaula, Prasiksha and Gadgeel, Manisha and Edwards, Holly and Polin, Lisa and Kushner, Juiwanna and Dzinic, Sijana H and White, Kathryn and Ge, Yubin and Taub, Jeffrey W and Gurdziel, Katherine and Dlugas, Hunter and Dyson, Greg and Arlene, Rozzelle and Carr, David and Moussa, Omar and Savaşan, Süreyya},
  title = {Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1396},
  doi = {10.3390/cancers18091396}
}
Kostenlos starten →